title: Treatment of mice with anti-CD86 mAb reduces CD8+ T cell-mediated CTL activity and enhances ocular viral replication in HSV-1-infected mice.
abstract: OBJECTIVE
  To determine the relative impact of the CD86 (B7-2) costimulatory molecule in protection against ocular HSV-1 infection.
  
  
  METHODS
  BALB/c mice were depleted of CD86 by antibody and depleted mice were examined for their ability to withstand HSV-1 ocular infection. Depleted mice were tested for the presence of virus replication, T-cell activation, survival, and eye disease.
  
  
  RESULTS
  Mice that had been depleted of CD86 had significantly higher titers of HSV-1 in their eyes compared to mock-depleted infected mice. However, the levels of corneal scarring between the two groups of mice were similar. Following ocular infection, the levels of class I MHC-restricted cytotoxic T lymphocytes (CTL) were significantly higher in mock-depleted mice than in CD86-depleted mice. Finally, adoptive transfer of primed CD8(+) T cells but not CD4(+) T cells to CD86-depleted mice resulted in a decrease in peak virus titers in the eyes, such that HSV-1 titers were similar to that of their mock-depleted counterparts.
  
  
  CONCLUSIONS
  These data demonstrate an important role for CD86 in the development of CTL and reduction of virus replication in the eyes of HSV-1-infected mice.
authors: Center for Neurobiology and Vaccine Development, Ophthalmology Research, Department of Surgery, CSMC Burns & Allen Research Institute, Los Angeles, CA 90048, USA.
authors: Yanira
authors: Y
authors: Osorio
authors: Steve
authors: S
authors: Cai
authors: Homayon
authors: H
authors: Ghiasi
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D051940:B7-2 Antigen; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002478:Cells, Cultured; D003315:Cornea / Q000473:pathology / Q000821:virology; D004195:Disease Models, Animal; D005260:Female; D005434:Flow Cytometry; D018259:Herpesvirus 1, Human / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D007111:Immunity, Cellular / Q000276:immunology; D007274:Injections, Intraperitoneal; D016849:Keratitis, Herpetic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008562:Membrane Glycoproteins / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D013154:Spleen / Q000276:immunology / Q000473:pathology / Q000821:virology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D008562:Membrane Glycoproteins